Skip to main content

Table 2 Frequency of drug use in MS patients

From: Polypharmacy in patients with multiple sclerosis: a gender-specific analysis

Drugs Female (N = 218) Male (N = 88) p valueFi FDRFi
Frequency of medication groupsc Frequency of medication groupsc
DMDs 92.7% 90.9% 0.641 0.859
Gastrointestinal drugs 42.7% 45.5% 0.703 0.859
Thrombosis prophylactics 37.6% 45.5% 0.246 0.673
Osteoporosis drugs 34.4% 37.5% 0.692 0.859
Dietary supplements 33.9% 23.9% 0.101 0.556
Sedatives 30.7% 23.9% 0.265 0.673
Analgesics 28.0% 20.5% 0.196 0.673
Antihypertensives 23.9% 28.4% 0.467 0.835
Thyroid drugs 20.2% 1.1% < 0.001 < 0.001
Antidepressants 19.7% 15.9% 0.518 0.835
Aconuresis drugs 18.8% 18.2% 1.000 1.000
Antispasmodics 17.9% 31.8% 0.010 0.110
Anticonvulsants 16.5% 18.2% 0.738 0.869
Contraceptives 16.1% 0.0% < 0.001 < 0.001
Common cold remedies 11.9% 8.0% 0.416 0.808
Antiinfectives 8.7% 4.5% 0.242 0.673
Cholesterol-lowering drugs 6.9% 11.4% 0.248 0.673
Fampridine 6.0% 14.8% 0.021 0.173
Diabetes drugs 5.5% 3.4% 0.567 0.835
Antiallergics 5.0% 2.3% 0.361 0.794
Anti-Parkinson drugs 5.0% 3.4% 0.764 0.869
Menopause medications 5.0% 0.0% 0.038 0.251
Eye drops 4.6% 1.1% 0.187 0.673
Asthma drugs 2.3% 1.1% 0.677 0.859
Dermatics 2.3% 0.0% 0.326 0.768
Antidementives 1.8% 0.0% 0.582 0.835
IT for comorbidities 1.8% 3.4% 0.414 0.808
Migraine medications 1.4% 0.0% 0.560 0.835
Neuroleptics 1.4% 0.0% 0.560 0.835
Antivertiginous drugs 0.9% 0.0% 1.000 1.000
Fatigue drugs 0.5% 2.3% 0.200 0.673
Uricostatics 0.5% 0.0% 1.000 1.000
VRA 0.5% 0.0% 1.000 1.000
  1. DMDs disease-modifying drugs, FDR adjusted p value according to false discovery rate, IT immunotherapy, N number of patients, VRA vasopressin receptor antagonists
  2. cProportion of patients in %
  3. FiFisher’s exact test